C5AR1 and COVID-19: To test whether our findings hold true at a center that had independently measured inflammatory markers in a similar time frame of patient enrollment, we utilized a second cohort from Yale School of Medicine, wherein C5a had been prospectively measured in the plasma of patients hospitalized with COVID-19 (Yale longitudinal cohort, N=23) within the first 24 hours of hospital admission.